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Compartmentalized cAMP signaling
cAMP was discovered in 1956 by Earl Sutherland 
as the original second messenger molecule that 
acts to transmit extracellular cues sensed by 
surface receptors into tangible physiological 
responses mediated by cAMP effector proteins 
(reviewed in [1,2]). Since its discovery, cAMP has 
been the subject of much research and is known to 
impinge on many essential cellular processes, such 
as immune function [3], growth [4], differentiation 
[5], gene expression [6] and metabolism [7].
In a cardiac setting, cAMP has a central role 
in the orchestration of excitation–contraction 
coupling, providing sympathetic stimulation 
following activation of b-adrenergic receptors 
(reviewed in [8]). Briefly, b-agonists, via binding 
to b-adrenergic receptors, stimulate the release of 
the Gas that binds to membrane-localized AC to 
trigger the production of cAMP. cAMP can then 
activate one of three cAMP-effector proteins, 
PKA, the EPAC or CNGC to evoke a cellular 
response (Figure 1) [9]. PKA can phosphorylate 
many of the calcium-handling proteins that 
coordinate excitation–contraction coupling 
(Figure 2), such as troponin I, RyR2, PLB and 
l-type calcium channels (LTCCs) causing an 
increase in the force and frequency of heart beat 
[10] and an increase in cardiac relaxation [11]. 
EPAC activation can also alter the dynamics of 
cardiac calcium flux during excitation–contrac-
tion coupling via phospholipase C signals [12,13] 
and it is suggested that CNGCs may promote 
chronotropic responses to agents that increase 
cellular cAMP [14].
One question that has fascinated those 
interested in cardiac cellular signaling is, 
how can one ubiquitous signaling molecule 
exert such a variety of sophisticated actions 
in the heart? The diffusion of cAMP is rapid 
(130–700 µm2 S-1) and should rapidly dis-
tribute from the outer membrane, through 
the entire cell, activating all cAMP effectors 
concomitantly. Groundbreaking work from 
Brunton and colleagues in the early 1980s 
reported that several G-protein-coupled 
receptors could trigger equivalent increases in 
cAMP but also resulted in each receptor type 
mediating a specific physiological outcome [15]. 
Brunton and colleagues proposed that one solu-
tion to this puzzle was that the cAMP response 
and the proteins mediating it were compart-
mentalized in some way (Figure 3) . Further 
work also proved that physical segregation of 
PKA within cardiac myocytes resulted in dif-
ferent subsets of PKA substrates being phos-
phorylated in response to activation of different 
receptor types [16]. In the field, we now know 
that the segregation of different PKA pools 
in cells depends on the scaffolding function 
of a variety of AKAPs (Figure 3) [17]. We also 
know that cAMP dynamics within heart cells 
are heavily influenced by cAMP PDEs, the 
only enzyme family that can degrade cAMP 
by hydrolysis [18]. The development of optical 
probes, which were able to report real-time, 
spatial and temporal changes in cAMP showed 
that spatially restricted cAMP gradients were 
formed in cardiac myocytes following addition 
Targeting protein–protein interactions within 
the cyclic AMP signaling system as a 
therapeutic strategy for cardiovascular disease
The cAMP signaling system can trigger precise physiological cellular responses that depend on the fidelity of many 
protein–protein interactions, which act to bring together signaling intermediates at defined locations within cells. 
In the heart, cAMP participates in the fine control of excitation–contraction coupling, hence, any disregulation of 
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of b-adrenergic stimuli [19]. These gradients 
are essential for tailoring receptor-specif ic 
responses because cAMP effectors such as PKA 
and EPAC are anchored at specific intracellular 
sites where they ‘read’ cAMP concentrations 
and instigate downstream signaling events. The 
cAMP gradients themselves could be shaped 
by discretely positioned PDEs that restrict the 
free diffusion of the cyclic nucleotide (Figure 3) 
[20] and/or structural impediments and local 
changes in viscosity [21]. However, it is recog-
nized that it is the equilibrium between cAMP 
synthesis by AC and the hydrolytic activity 
of the PDE complement of the cardiac myo-
cyte that controls magnitude and duration of 
cAMP-dependent signaling processes [22]. 
In summation, the fidelity of compartmen-
talized cAMP signals that result in receptor 
specific physiological changes in cardiac myo-
cytes depend on the position of the enzymes 
that synthesize the second messenger (AC at 
the plasma membrane), the localization of the 
enzymes which hydrolyze cAMP (targeted 
PDEs) and the anchoring of cAMP-effector 
proteins (PKA, EPAC) that act to convert 
‘cAMP currency’ into actual cellular responses. 
Adr
Adr
Adr Adr
AC
GTP
cAMP
Signal transduction
PKA EPAC CNGC
PKA EPAC CNGC
UCR2 UCR1
PDE4D5
catalytic N-terminal
P
PGαs Gαs
7 1 2 7 1 24 45 5
Enhanced excitation–contraction coupling
Signal termination
β adrenergic receptor
Future Med. Chem. © Future Science Group (2013)
Arrestin
Figure 1. cAMP signaling pathway. (A) Hormones such as adrenaline bind to G-protein-coupled receptors such as the b-adrenergic 
receptors, stimulate the release of the Gas that binds to membrane-localized AC to trigger the production of cAMP. cAMP can then 
activate one of only three cAMP-effector proteins, PKA, the EPAC or cyclic nucleotide-gated ion channels to promote downstream 
signaling that promotes sympathetic cardiac stimulation. Note that CNGC are transmembrane proteins that locate to the plasma 
membrane whereas PKA and EPAC can be targeted to many different intra-cellular locations depending on the identity of the anchor 
proteins to which they are sequestered. (B) b arrestin mediates translocation of PDE4D5 in heart and airway cells following activation 
of the b2-adrenergic receptor. This action terminates signaling to the cAMP effector proteins, PKA and possibly the EPAC and cyclic 
nucleotide-gated ion channels. The modular structure of PDE4D5 is depicted demonstrating the N-terminal targeting region, upstream 
conserved regions that regulate enzyme activity and the catalytic domain.
Key Term 
PDEs: Super-family of enzymes 
that have the unique ability to 
hydrolyze the cyclic-nucleotides 
cAMP and cGMP. There are 11 
known families (PDE1–11) with 
PDE4, 7 and 8 being cAMP 
specific, PDE5, 6 and 9 being 
cGMP specific and the other five 
(PDEs 1, 2, 3, 10 and 11) having 
dual specificity with differing 
affinities for both types of cyclic 
nucleotide.
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Disregulation of certain signaling responses at 
these nodes can result in cardiovascular dis-
ease and the cAMP signaling system in car-
diac cells has long been regarded as an axis 
that could be targeted as a therapeutic route 
[23–25]. However, as PKA, EPAC and PDEs are 
ubiquitous proteins that undertake numerous, 
unrelated functions in a cell or tissue, active 
site directed inhibitors, which act nonspecifi-
cally to prohibit equally the activity of com-
plete enzyme families, would have an increased 
chance of inducing serious ‘off-target’ effects. 
With this in mind, a more sensible approach 
would be to target specific protein–protein 
interactions that underpin the compartmen-
talization of EPAC, PKA and PDEs. In this 
way, it should be possible to isolate and dis-
place the activity of a single ‘pool’ of one of 
these enzymes so that any treatment would not 
impinge on the other activities of the enzyme 
in question. This may combat the action of 
a hyper- or hypo-activated cAMP-effector 
enzyme (PKA or EPAC) or compensate for the 
reduced/increased activity of a mutated PDE 
or AC. This type of research is in its infancy 
and the aim of this review is to highlight recent 
advances and discuss on-going problems in 
this area.
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Figure 2. PKA promotes sympathetic stimulation of heart function. b-adrenergic stimulation via adrenaline results in the 
activation of localized pools of PKA that act to phosphorylate a number of proteins, which orchestrate excitation–contraction coupling. 
In a coordinated fashion, PKA directly phosphorylates the LTCC, RyR2, PLB and troponin I to promote calcium (Ca2+) influx, calcium 
release from intracellular sarcoplasmic stores, cardiac muscle contraction and calcium reuptake. 
LTCC: l-type calcium channels; SR: sarcoplasmic reticulum.
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Disruption of phosphodiesterase 
targeting
PDEs have been classed into eleven families 
(PDE1–11), with PDE5, 6 and 9 being cGMP 
specific, PDE4, 7 and 8 being cAMP specific 
and the other five PDEs (PDE1, 2, 3, 10 and 11) 
having dual specificity with differing affinities 
for both types of cyclic nucleotide [26]. As the 
various PDE families are encoded by multiple 
genes, with alternate splicing sites and alter-
nate promoters, the number of transcripts is 
large, and this results in the expression of a 
highly diverse group of enzymes with divergent 
functions [27].
In this article we focus on the cAMP-specific 
PDE4 family as it has provided much insight into 
cAMP signal compartmentalization in cells of the 
cardiovascular system [22]. PDE4s are encoded 
by four genes (A, B, C and D) and these give 
rise to at least 25 different proteins (six PDE4A 
forms, five PDE4B forms, three PDE4C forms 
and 11 PDE4D forms) via mRNA splicing and 
promoter diversity [28]. Indeed, study of this PDE 
family has provided the paradigm for intracellular 
targeting of cAMP hydrolysis and this is because 
all PDE4 isoforms have similar K
ms
 and V
max
 for 
cAMP hydrolysis, hence their functional role 
is determined largely by their cellular location, 
interaction with other signaling proteins and post-
translational modification. In keeping with all 
other PDE families, PDE4s have a complex mod-
ular structure, consisting of a conserved catalytic 
domain, sub-family specific C-terminal domain, 
dual regulatory domains called upstream con-
served region 1 and upstream conserved region 
2 together with an isoform specific N-terminal 
region (Figure 1) [28]. Importantly, in the context 
of this review, the fundamental roles that individ-
ual PDE4 isoforms play in tailoring compartmen-
talized cAMP signals are conferred by the unique 
localization sequences that are contained within 
isoform-specific N-terminal regions. This ‘post-
code’ sequence or other localization sequences 
direct the association of PDE4 family members 
to a variety of inert scaffolds, lipids or active pro-
teins. These include RACK1 [29], b-arrestin [30], 
AKAP18 [31], b1-adrenergic receptor [32], immu-
nophillin XAP2 [33], mAKAP [34,35], SRC family 
tyrosine kinase [36], the dynein complex member 
Nudel [37], the p75 neurotrophin receptor[38], 
DISC1 [39], the cardiac IKs potassium channel 
[40], the PDZ domain containing protein Shank2 
[41] and phosphatidic acid [42,43]. 
It has been known for some time that inhibi-
tors directed against the active site of PDE4 iso-
forms have great potential for the treatment of 
a variety of diseases (reviewed in [28,44]). How-
ever, in practice, their clinical utility is com-
promised by side effects that limit maximally 
tolerated doses [45]. Headache, nausea, emesis 
and diarrhea are the most commonly reported 
side effects and these stem from the inhibition 
of PDE4 isoforms in non-target tissues. Spe-
cifically, PDE4D expression is high in an area 
of the brain known to trigger nausea called 
the area postrema [45]. Despite the disadvan-
tages of PDE4 inhibitors, one such compound 
(roflumilast) has recently been approved by the 
European Commission and US FDA for the 
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Figure 3. Spatially restricted cAMP gradients are shaped by discretely 
positioned PDEs. Following addition of b-adrenergic stimuli, receptor specific 
responses depend on the positioning of localized pools of PDE that shape cAMP 
gradients (purple) within defined cellular compartments. This action allows fine 
control of the magnitude and duration of cAMP-dependent signaling processes 
that depend on the activation of cAMP-effector proteins PKA as demonstrated in 
this diagram, which ‘read’ local cAMP concentrations. AKAPs sequester PKA to 
defined cellular compartments. 
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treatment of severe chronic obstructive pulmo-
nary disease [46], however, there is still concern 
over side effects such as diarrhea, pancreatitis 
and weight loss associated with taking the drug 
[47]. One route to aid development of a novel, 
safer class of PDE4 inhibitor would be to target 
the protein–protein interactions that underpin 
the enzyme’s localization. The unique, non-
redundant roles that PDE4 isoforms play [48] 
in shaping compartmentalized cAMP signals 
have only recently been discovered using novel 
technologies such as siRNA knockdown [49], 
dominant negative transfection of catalytically 
dead PDE4 isoforms [50], knockout mice [51] 
and peptide interference [52]. The first three of 
these approaches represent powerful techniques 
for elucidating the functions of anchored PDE4 
isoforms, however, they are limited by the fact 
that they target all subpopulations of the same 
isoform. This may render investigation of func-
tional outputs problematic for isoforms such as 
PDE4D5, which have multiple non-redundant 
functions within the same cell or tissue [20]. The 
peptide interference approach, in comparison, 
targets the disruption of PDE4 cellular target-
ing rather than PDE catalytic activity and, as 
such, can be used to investigate the function 
of different ‘pools’ of the same isoform. The 
technique relies on accurate peptide mapping 
of the protein–protein interactions that anchor 
PDE4 isoforms (or any other protein target) 
to their scaffolds. Such information has been 
facilitated by the introduction of peptide array 
technology, a technique that allows rapid deter-
mination of the molecular nature of protein–
protein interactions [53]. A library of spotted, 
immobilized peptides (overlapping peptides up 
to 25mers, each shifted by five amino acids) of 
the PDE4 localization sequence can be probed 
by a purified, recombinant form of the PDE4 
scaffolding protein using a simple ‘far-western’ 
overlay protocol. Positive spots contain puta-
tive binding sequences that can then be used to 
inform mutagenesis studies on the PDE4 iso-
form to both verify the sites of interaction and 
probe for novel PDE4 functions. The identified 
sequences can also be converted into powerful 
small peptide agents that have the potential 
to interfere with protein interactions in vivo. 
This disruption approach has been used exten-
sively in the cAMP signaling field to investi-
gate the purpose of interactions between PDE4 
enzymes and the signaling proteins RACK1 
[29], b arrestin [29,30] and the cardioprotective 
chaperone HSP20 [54]. Of these examples, the 
latter two offer therapeutic potential in the 
cardiovascular area.
Disruption of the PDE4D5–b arrestin 
complex
There is now a large body of evidence to suggest 
that b arrestin, a multifunctional scaffold protein, 
orchestrates the dynamic redistribution of the 
PDE4 isoform PDE4D5 in heart and airway cells 
following activation of the b2-adrenergic recep-
tor [55–60]. Indeed, the involvement of PDE4D5 
in the b-adrenergic response constitutes the first 
example of a biological function ascribed to a 
single PDE4 isoform and represents the initial 
realization that although PDE4 isoforms are 
tethered, that did not mean they were static but 
instead could be translocated in conjunction 
with other proteins to sites of high cAMP con-
centrations within the cell [48]. Thus, the b arres-
tin–PDE4D5 complex [59] is shuttled to activated 
b2-adrenergic receptors so that an active pool of 
PDE4 is recruited to the site of cAMP synthesis 
to initiate the desensitization process (Figure 1B) 
[22]. This action is in synergy with the primary 
function of b arrestin, which is to sterically hin-
der signaling between receptors and G
s
, initiating 
a reduction in AC activation and a subsequent 
decrease in cAMP production [61]. In effect, the b 
arrestin–PDE4D5 complex serves to orchestrate 
a dual desensitization process where the ‘message’ 
is destroyed at the same time as the receptor’s 
signal to the G-protein is silenced. This, in turn, 
effectively ‘resets’ the receptor for another round 
of agonist challenge. The dynamic movement of 
PDE4 also down regulates PKA phosphorylation 
of the b2-adrenergic receptor by the AKAP79–
PKA complex [62]. This action promotes switch-
ing of b2-adrenergic receptor signaling via AC 
activation through G
s
, to inhibition via G
i
 and 
subsequent activation of the ERK–MAP kinase 
pathway [9].
As eluded to above, a novel approach directed 
against the targeting of PDE4D5 to specific 
signalosomes, such as the scaffold protein, b 
arrestin has been facilitated by the introduction 
of peptide-array technology. Fine mapping of 
the b arrestin association site within the unique 
N-terminal of PDE4D5 has allowed determina-
tion of minimal sequences which are essential to 
promote the interaction between PDE4D5 and 
b arrestin [29,30] and these have been modeled on 
the NMR structure of the PDE [52] and verified 
using yeast-2 hybrid ana lysis and site-directed 
mutagenesis [29]. Cell-permeable versions of 
these sequences have provided ‘proof-of-concept’ 
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for this approach as they demonstrated that dis-
turbance of targeted pools of one PDE4 isoform 
could result in a distinct functional change. In 
this case, attenuated recruitment of PDE4D5 to 
the b2-adrenergic receptor leading to a hyper-
phosphorylation of the receptor after stimulation 
[52]. Interestingly, disruption of the binding of 
PDE4D5 to another binding partner, the scaf-
fold RACK1 [63], using a different sequence, 
led to a very different outcome where PDE4D5 
recruitment to the leading edge of cancer cells 
was attenuated. This action served to inhibit the 
formation of spreading initiation centers, pre-
vent cell spreading and block cell polarization 
toward the leading edge of a wound created in a 
confluent monolayer [64].
Disruption of the PDE4–HSP20 
complex
HSPs are a ubiquitous and diverse group of 
chaperone proteins that are essential for the 
maintainance of normal cell metabolism. The 
expression of these proteins is rapidly upregu-
lated during the protective response following 
periods of cellular stress and this action protects 
the cell from various kinds of damage [65]. HSPs 
have been organized into families on account 
of their molecular weight and function. Small 
HSPs are the most diverse family and are known 
for their intrinsic chaperone function as well as 
the protective effects they confer in neurology 
and cardiology settings [66]. Recently, one of the 
ten small HSPs, HSP20 (HSPB6), has been a 
focus of interest in the field of cardiovascular 
research. The most widely studied protective 
capabilities of HSP20 are in the field of car-
dioprotection, where its actions can be broadly 
divided into anti-ischemic, anti-apoptotic and 
anti hypertrophic effects (reviewed in [67,68]). 
Many of the cardio protective effects under-
pinned by HSP20 are known to depend on 
phosphorylation of a PKA site in the N-terminal 
region of HSP20 (Ser16) [69]. This action is pro-
moted by HSP20s association with AKAP–Lbc 
[70] and inhibited by its association with PDE4 
[71]. Enzymes of the PDE4 family associating 
with HSP20 act as local cAMP sinks to create 
areas devoid of the cyclic nucleotide, and thus 
prevent the phosphorylation of HSP20, unless 
either the PDE4 is inhibited or the rate of cAMP 
production rises so as to saturate the pool of 
PDE4 associated with the chaperone (Figure 4) 
[54]. Thus, chronic b-adrenergic stimulation, 
with a constant activation of AC and sustained 
increases in local cAMP levels, saturate the 
PDE4 pool localized to HSP20, allowing PKA 
activation and phosphorylation of sequestered 
HSP20. In times of low basal cAMP, however, 
the association with PDE4 prevents HSP20 
phosphorylation and ‘activation’ of its cardio-
protective abilities. In an attempt to devise an 
agent that could permanently ‘switch on’ theses 
abilities, the site of interaction between HSP20 
and PDE4 was mapped using a peptide array. 
The binding site was found to be within the 
PDE4 catalytic region and a cell-permeable 
peptide based on that sequence was shown to 
disrupt the HSP20–PDE4 complex and induce 
HSP20 phosphorylation under basal conditions 
(Figure 4) [54]. Pretreatment of cardiac myo-
cytes with the disruptor peptide but not with 
a scrambled version also afforded protection 
against the hypertrophic response following 
chronic b-adrenergic stimulation. Expression 
levels of the cardiac chaperone, HSP20, have 
been found to increase in response to hyper-
trophic stimuli such as aortic constriction and 
chronic b-adrenergic receptor agonist treat-
ment [72]. Protection against hypertrophy has 
also been seen in transgenic mice overexpressing 
HSP20 [73] and this has been linked to a rise 
in the levels of phospho-HSP20. Moreover, a 
phospho-mimic mutant of HSP20 (Ser16 to Asp 
substitution) expressed in isolated adult cardiac 
myocytes conferred full protection from chronic 
b-adrenergic stimulation-induced apoptosis, 
whereas the phospho–null (Ser16 to Ala) did not 
[74]. It is noteworthy that the same mouse model 
(overexpressing phospho-null HSP20) was also 
negative for protection against I/R injury [75] and 
these results highlight the importance of Ser16 
modification in switching HSP20 from a dor-
mant form to the cardioprotective, phosphory-
lated state. Some experimental success has been 
achieved with simple cell permeant phospho–
peptide analogues encompassing the vital PKA 
consensus site in the N-terminus. Such peptides 
may confer protection against a variety of dis-
eases including subarachnoid hemorrhage [76], 
vasospasm of human umbilical artery [77], keloid 
scarring [78], airway smooth muscle relaxation 
[77,79] and platelet aggregation [80]. Clearly, all of 
these peptide agents have therapeutic potential, 
with one, namely AZX100 [81] having undergone 
Phase II clinical trials. However, it is important 
to point out that the potency of such peptides 
could be limited by the fact that the sequence 
from which they are comprised does not con-
tain the a–crystalin domain, a region required 
for many HSP20 functions. The sequences also 
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contain an unstable phosphate group, which can 
be easily targeted by phosphatases and is difficult 
to mass produce. So, the strategy of inducing 
endogenously expressed phospho-HSP20 by dis-
placing associated PDE activity, in comparison, 
should circumvent these problems.
Other medical advantages conferred by HSP20 
may be discovered following experimentation 
into adenoviral gene delivery of HSP20 and viral 
delivery of shRNA to silence the HSP20 expres-
sion. Drug screening of small-molecule libraries 
could also be a lucrative strategy to harness the 
therapeutic potential of HSP20. If compounds 
can be found that mimic the action of peptides 
discussed above, then these would be easier to 
convert into useable therapeutics. This approach 
has been validated by a recent study, which dis-
covered small-molecule modulators of HSP20 
signals that caused relaxation of human airway 
smooth muscle cells and intact tissue ex vivo [71].
Disruption of complexes that alter 
EPAC signaling
Cell-permeable peptides designed to antagonize 
protein–protein interactions between PDE4 
enzymes and EPACs also have recently been dem-
onstrated to afford selective regulation of certain 
compartmentalized cAMP-mediated events in 
cells. For instance, PDE4-mediated hydroly-
sis of a plasma membrane pool of cAMP was 
recently shown to regulate the ability of EPAC1 
to stabilize VECAD–based adherens junctions 
(AJs) in vascular endothelial cells (VECs) and 
consequently control paracellular transport of 
cells or biomacromolecules across the endothe-
lium [5,82,83]. Indeed, inhibition of VEC PDE4 
activity increased cAMP, promoted EPAC1-
dependent Rap1 activation, strengthened VEC 
AJs and consequently decreased paracellular 
VEC transport. Since inhibition of another 
cAMP-hydrolyzing VEC PDE, namely PDE3, 
with cilostamide also increased VEC cAMP and 
activated EPAC1, but did not influence para-
cellular transport in these cells, the selective 
action associated with PDE4 inhibition were 
perhaps best explained through local effects. 
Consistent with this, VECs AJs were shown to 
assemble a VECAD-based complex containing 
b-catenin, p120-catenin, PDE4D, EPAC1 and 
Rap1. Moreover, treatment of these cells with 
a stearated EPAC1-based PDE4D displacing 
peptide promoted Rap1 activation within this 
complex and increased barrier stability to an 
extent similar to that afforded by pan-cellular 
PDE4 inhibition with the PDE4 inhibitor, 
rolipram (Figure 5) [84]. When the barrier sta-
bilizing actions of the EPAC1-based PDE4D-
displacing peptide were compared with those 
associated with those resultant from PDE4D 
knockdown, a critical role for PDE4D in pro-
moting integration of EPAC1 into the VECAD-
based complex was observed. Although not yet 
fully deciphered, clearly this second effect likely 
involves additional protein–protein interactions 
between PDE4D and EPAC1, or PDE4D and 
other members of this signaling complex, which 
could be targeted. 
Notwithstanding the observation that PDE3 
inhibitor–induced activation of EPAC1 did not 
alter VEC permeability, it did impact integrin-
based adhesion, migration and tubule formation 
Future Med. Chem. © Future Science Group (2013)
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Figure 4. Peptide disruption of the HSP20–PDE4 complex promotes PKA 
phosphorylation of HSP20 on serine 16 to trigger its cardioprotective 
action. Peptide array mapping of the HSP20 binding site on PDE4 informed the 
discovery of a disruptor peptide that could dissociate the complex. This action 
serves to release the ‘brake’ on PKA pools that localize with HSP20 (PKA not 
shown here) and promote the phosphorylation of HSP20 on Ser16. Many of the 
cardioprotective effects underpinned by HSP20 are known to depend on HSP20 
phosphorylation.
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by VECs [85]. Indeed, these events are coordi-
nated locally in a human VEC complex com-
posed of EPAC1/R-Ras/p84-p110g and teth-
ered to the plasma membrane by PDE3B [85]. In 
addition, since PDE3B interacted directly with 
EPAC1 and with the p84 regulatory domain of 
PI3Kg [86,87] via distinct peptide motifs, PDE3B 
simultaneously tethers each EPAC1 and the 
p84-regulated form of PI3Kg to membranes in 
these cells. Consistent with this, PDE3 inhibi-
tion with cilostamide, selective PDE3B knock-
down or addition of a PDE3B-based EPAC1-
displacing peptide in HAECs each promoted 
EPAC1-dependent activation of R-Ras, activated 
the p84-regulated form of PI3Kg and promoted 
downstream signaling through both ERK and 
PKB [85]. These findings, when combined with 
those obtained using the EPAC1-based PDE4D 
displacing peptide discussed above, validate the 
concept that selective regulation of individual 
cAMP-sensitive cellular events can be achieved 
with reagents, or drugs, able to selectively disturb 
the formation of individual cAMP–signalosomes 
that signal through EPAC1 in cells. This may 
be important for the development of antihyper-
tophy therapeutics as the EPAC signaling axis 
has recently been highlighted as a major route 
for the promotion of the hypertrophic effect of 
chronic b-adrenergic receptor activation [88,89] 
via a mechanism involving H-Ras, phospholipase 
C and HDAC4 translocation [90]. In addition, an 
EPAC-PDE4D5 signaling axis has recently been 
recognized as being important in the direction 
sensing process of migration of cancer cells [91].
Disruption of AKAP complexes
AKAPs are a family of proteins that are instru-
mental in the maintenance of distinct cAMP 
signaling compartments in cells, such as those of 
the heart [92]. They comprise a group of proteins 
that bind and anchor PKA (a complex consist-
ing of two regulatory subunits [R] that bind to 
and inhibit two catalytic subunits [C]), thereby 
acting to sequester and localize the enzyme in 
the vicinity of its substrates and other signaling 
proteins that may impinge on PKA function 
such as phosphatases and other kinases. As such, 
AKAPs are signaling hubs that organize down-
stream cardiac signals that are driven by PKA, 
whilst also serving as crosstalk junctions that 
allow integration of multiple signaling cascades 
[93]. AKAPs represent a new and emerging target 
for drug development for chronic heart failure 
[23]. A 14–18-amino acid sequence is common 
to many AKAPs, which allows anchoring to the 
regulatory subunit dimer of PKA. This series 
of residues creates an amphipathic a helical 
structure, which fits into a hydrophobic groove 
generated by the dimerized regulatory subunits 
[94]. Over the years, many types of AKAP have 
been discovered, with the majority being RII-
binding AKAPs [95], although some AKAPs 
with specificity in anchoring of the RI-type sub-
units have been reported [96]. Additionally, dual 
specificity AKAPs have been identified, which 
possess the ability to bind both type I and type 
II PKAs [97]. As a single AKAP can influence 
the PKA phosphorylation of many substrates 
(e.g., AKAP79 directs phosphorylation of ACs 
5, 6 and 8 [98,99], the b2-adrenergic receptor [62], 
b1-adrenergic receptor [100], Kir2.1 potassium 
channel [101], GluR1 [102], the vallanoid receptor 
TRPV1 [103] and GABA receptors [104]), disrup-
tion of the AKAP–PKA interface has helped in 
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Figure 5. Peptide disruption of the PDE–EPAC complex reduces vascular 
endothelial cell permeability. A disruptor peptide corresponding to the PDE4 
docking site on EPAC disrupted the PDE4–EPAC complex, allowing the activation 
of EPAC by cAMP. This action promotes EPAC1-dependent Rap1 GTPase 
activation, strengthens VEC adherens junctions and consequently decreases 
paracellular VEC transport.
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characterizing a range of functions for specific 
AKAP types in a variety of cells/tissues. Cell-
permeable peptides that displace PKA from 
AKAPs have helped delineate AKAP function 
in Tcells [105], pancreatic b cells [106], adrenocor-
tical cells [105], cardiac myocytes [107,108], hip-
pocampal neurons [109] and renal principal cells 
(reviewed in [110]). 
Approximately a third of all known AKAPs 
are expressed in heart tissue and it is now estab-
lished that AKAP-scaffolding proteins are vital 
for the spatial and temporal modulation of 
cardiac excitation–contraction coupling and 
the maintenance of healthy cardiac physiol-
ogy. AKAPs can be linked to Ca2+ influx, Ca2+ 
release and re-uptake of Ca2+ from sarco plasmic 
reticulum calcium stores as well as myocyte 
repolarization and cardiac remodeling follow-
ing hypertrophic stimuli (reviewed in [111]). 
Although our appreciation of AKAP function 
has dramatically increased over the last decade, 
little progress has been made at the organism 
level, as mouse ‘knockout’ models have failed 
to shed much light on the functional signifi-
cance of AKAP-signaling in cardiac disease 
[111], although some progress has been made 
with ‘knock in’ mice in the field of pain man-
agement [103]. It has been suggested that this 
may be due to the fact that genetic silencing of 
AKAPs may not enable researchers to differenti-
ate between modular and integrative roles that 
AKAPs take [111] and one way round this prob-
lem would be to design peptides or small mol-
ecules that selectively target functional domains 
on AKAPs rather than AKAPs themselves or the 
AKAP–PKA interface. This method has proved 
useful in the elucidation of how AKAP15 regu-
lates rapid and efficient PKA phosphorylation of 
Ca2+ channels and increases the l-type calcium 
current through CaV1,2 channels in isolated 
cardiac myocytes [112] and skeletal muscle [113]. 
In these cases, the AKAP associates directly 
with the C-terminal region of the a subunit 
of the Ca2+ channel via a leucine zipper motif. 
Peptides that inhibit PKA, displace PKA from 
AKAP15 or displace AKAP15 from the Ca2+ 
channel, all significantly reduce voltage depen-
dent potentiation of the channel and blocks 
efficient regulation of l-type Ca2+ currents in 
response to b-adrenergic stimulation. A similar 
approach was used to highlight the importance 
of AKAP18d in calcium reuptake during excita-
tion–contraction coupling [114]. SERCA plays a 
vital role in Ca2+ homeostasis by driving calcium 
reuptake. SERCA is inhibited constitutively by 
PLB and this inhibition is released following 
phosphorylation of PLB by PKA. AKAP18d 
coordinates PLB phosphorylation and, hence, 
orchestrates calcium dynamics in cardiac myo-
cytes. Mapping the AKAP18d interaction site 
on PLB allowed invention of a disruptor peptide 
that could effectively displace the AKAP from 
PLB and SERCA. This resulted in a significant 
depression of PLB phosphorylation and slower 
reuptake of Ca2+ into the sarcoplasmic reticulum 
under basal conditions or following norephi-
nephrine stimulation [114]. Pharmacologic tools 
that can selectively ‘unhook’ PKA from a single 
cardiac substrate could be used to determine 
the role of signaling scaffolds in the response of 
failing myocardium to catecholamines and cat-
echolamine antagonists. The AKAP18d disrup-
tor may also represent a way of manipulating the 
SERCA–PLB–PKA complex in investigations 
to combat post-infarction heart failure caused 
by aberrant PLB function [115,116].
Much effort has been expended in charac-
terizing an AKAP-tethered signaling complex 
that regulates hypertrophic signaling in cardiac 
myocytes [117]. mAKAP integrates signals from 
the cAMP and MAPK cascades by virtue of a 
unique set of binding partners that include PKA, 
PDE4D3, the phosphatases, PP2A and calcineu-
rin, EPAC1 and the MAPKs, MEK5 and ERK5 
[34], and RSK [118]. Orchestration of signals by 
mAKAP allows two separate negative feedback 
loops for cAMP where, in the first instance, 
PKA phosphorylation of PDE4D3 results in an 
activation of PDE4 and an increase in affinity 
of the enzyme for mAKAP. The overall effect 
is an increase in recruitment of active PDE4 to 
the mAKAP signalosome, an event that opposes 
PKA activation. In the second mode, cAMP 
activates EPAC which then activates Rap1. Rap1 
inhibits MEK5 causing a reduction in the inhibi-
tory phosphorylation of PDE4D3 by ERK5 [34]. 
This increases localized PDE4 activity, again, 
reducing local cAMP levels and PKA activity. 
Recently, it has also been demonstrated that the 
RSK component of the mAKAP hub is known 
to be important in the maintenance of signal-
ing required for the initiation of hypertrophy in 
cardiac myocytes [118]. Peptides corresponding to 
the RSK docking site on mAKAP, inhibited the 
hypertrophy of cultured myocytes and could rep-
resent novel tools that could be developed for the 
prevention and treatment of heart failure.
Although peptide inhibitors of AKAP func-
tion have proved useful in studying the possible 
roles of these anchor proteins in disease, poor 
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membrane permeability and lack of oral appli-
cation severely limit their therapeutic potential. 
Such problems can be circumvented by the use 
of small molecules. The only small-molecule 
inhibitor of AKAP–PKA interactions to be dis-
covered thus far, by high-throughput screening, 
works allosterically by binding to a region on 
the regulatory subunits of PKA, inhibiting its 
association with the AKAP of choice [119]. The 
compound also activates PKA and can dramati-
cally enhance the phosphorylation of PLB and 
cardiac troponin-I following b-adrenergic stim-
ulation without affecting the phosphorylation of 
a variety of other PKA substrates (Figure 6). This 
dual action serves to increase the contractility of 
cultured adult rat cardiac myocytes and isolated 
whole hearts [119]. This new class of molecule 
can now be tested in animal studies, however, 
its potential as a compound for the treatment of 
diseases that are underpinned by aberrant cAMP 
signaling is unclear.
Future perspective
There is a growing realization that cAMP-
signaling in cells occurs in a compartmental-
ized fashion and that PDEs, cAMP effectors 
and AKAPs play a central role in coordinating 
these local effects. Based on this appreciation, a 
consensus is emerging that selective modulation 
of the myriad effects coordinated by cAMP in 
cells will necessitate the use of agents capable 
of acting within specific compartments. Rising 
evidence, suggest that disruptor peptides may 
represent a valid strategy to achieve this goal. 
Future studies, aimed at determining how indi-
vidual cAMP-signalosomes are constructed, and 
in identifying the protein–protein interactions 
that represent their ‘achilles heel’ should pro-
mote the synthesis and testing of more disruptor 
peptides and small molecules. These studies will 
be bolstered by continued biochemical analyses 
such as those described here and with the imple-
mentation of high-resolution structural informa-
tion in the nature of the protein–protein inter-
actions that underpin their formation. Peptides 
disrupting defined protein–protein interactions, 
formulated for direct use, or peptidomimetics 
based on their structures, are likely to give rise 
to future biological tools with greater selectiv-
ity. This approach may be particularly relevant 
against discretely targeted PDE isoforms, which 
modulate the intricate process of excitation–
contraction coupling. Recent evidence suggests 
that spatially confined populations of tethered 
PDE4s in the heart, generate localized ‘sinks’ 
down which cAMP ‘disappears’ as it is converted 
into 5´ -AMP [20]. So far, the PDE4 compliment 
associated with the b1-adrenergic receptor [32], 
b2-adrenergic receptor [59], RyR2 [120], PLB [121] 
and LTCC [122] have been identified. Develop-
ment of disruptors against the targeting of these 
localized PDE4 pools would provide further 
insight into the non-redundant functions of 
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Figure 6. Small-molecule disruptors of the AKAP18d–PKA interaction 
promote contractility in cardiac myocytes. Allosteric regulation of PKA 
regulatory subunits by a small molecule inhibitor releases PKA from AKAP18d 
while concomitantly activating the kinase. This action promotes a hyper-
phosphorylation of PLB diminishing its inhibitory effect on the SERCA. As a result, 
calcium reuptake into the sarcoplasmic reticulum is enhanced and cardiac 
contractility is improved.  
SM: Small molecule Inhibitor; SR: Sarcoplasmic reticulum.
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these enzymes and provide novel routes of devel-
opment for therapeutics that improve cardiac 
function.
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Executive summary
 cAMP signaling in cells occurs in a compartment-specific manner.
 PDEs play a critical role in establishing and maintaining the signaling complexes which coordinate this compartmentalization.
 While a number of PDE inhibitors have found utility in the clinic, since these agents act by competing cAMP binding at the active site, 
they represent pan-compartment inhibitors and do not allow compartment-selective actions.
 Disruptor peptides (DPs) designed to compete the protein–protein interactions which bring together the individual components of the 
signaling complexes involved in the propagation of cAMP signals, represent a modality through which compartment-selective actions 
can be achieved.
 Several DPs that markedly and specifically impact cellular functions by inhibiting the formation of intracellular signaling complexes have 
been developed.
 Since DPs specifically inhibit binding between proteins in specific cAMP-signalosomes, these agents will allow regulation of cAMP-
mediated events selectively within individual cAMP signalosome-based compartments and, thus, will provide increased selectivity over 
that offered by agents that do not discriminate between these compartments but rather affect global cAMP signaling.
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